The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with...

Utilizing 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT), we performed this pilot study to evaluate the link between cytogenetic/genomic markers and imaging patterns in relapsed/refractory (RR) multiple myeloma (MM). We retrospectively analyzed data of 24 patients with RRMM who were treated at our institution between November 2018 and February 2020. At the last relapse/progression, patients had been treated with a median of three (range 1-10) lines of therapy. Six (25%) patients showed FDG avid extramedullary disease without adjacency to bone. We observed significantly higher maximum standardized uptake values (SUV_max) in patients harboring del(17p) compared with those without del(17p) (p = 0.025). Moreover, a high SUV_max of >15 indicated significantly shortened progression-free survival (PFS) (p = 0.01) and overall survival (OS) (p = 0.0002). One female patient exhibited biallelic TP53 alteration, i.e., deletion and mutation, in whom an extremely high SUV_max of 37.88 was observed. In summary, this pilot study suggested a link between del(17p)/TP53 alteration and high SUV_max on 18F-FDG PET/CT in RRMM patients. Further investigations are highly warranted at this point.